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Pre-Exposure Cybersickness
Assessment Within a Chronic Pain
Population in Virtual Reality
Phillip Brown* and Wendy Powell
Department of Cognitive Science and Artificial Intelligence, Tilburg University, Tilburg, Netherlands
Virtual Reality (VR) is being increasingly explored as an adjunctive therapy for
distraction from symptoms of chronic pain. However, using VR often causes
cybersickness; a condition with symptoms similar to those of motion and
simulator sickness. Cybersickness is commonly assessed using self-report
questionnaires, such as the Simulator Sickness Questionnaire (SSQ), and is
traditionally conducted post-exposure. It’s usually safe to assume a zero baseline
of cybersickness as participants are not anticipated to be exhibiting any sickness
symptoms pre-exposure. However, amongst populations such as chronic pain
patients, it’s not unusual to experience symptoms of their condition or medication
which could have a confounding influence on cybersickness symptom reporting.
Therefore, in population groups where illness and medication use is common,
assuming baseline is not necessarily desirable. This study aimed to investigate
cybersickness baseline recordings amongst a chronic pain population, and
highlights how deviations from an assumed baseline may incorrectly infer adverse
effects arising from VR exposure. A repeated measures study design was used, in
which twelve participants were assessed pre and post VR exposure via SSQ.
Significant differences were found between actual and assumed pre-exposure
baseline scores. Furthermore, we found significant differences between actual and
assumed increases in cybersickness scores from baseline to post exposure. This
study highlights that clinical sub-populations cannot be assumed to have a zero
baseline SSQ score, and this should be taken into consideration when evaluating the
usability of VR systems or interventions for participants from different demographics.
Keywords: virtual reality, cybersickness, chronic pain, self-report, baseline, pre-exposure
INTRODUCTION
Virtual Reality (VR) is being used more often in medical and scientific research, for a variety of
applications (Riva, 2005; Malloy andMilling, 2010; Valmaggia et al., 2016; Vaughan et al., 2016), and
has been demonstrated as a powerful and flexible technology which is also affordable and relatively
easy to use.
However, in spite of the rich potential of this technology for use in healthcare, it is common for
persons to prematurely exit a VR experience because of symptoms associated with cybersickness
(McCauley and Sharkey, 1992; Garrett et al., 2017). Cybersickness is defined as onset of nausea,
oculomotor, and/or disorientation while experiencing virtual environments (Rebenitsch and Owen,
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2016). This can cause problems for VR users as discomfort caused
as a result of cybersickness prevents interaction longevity (Davis
et al., 2015).
Symptoms of cybersickness can include nausea, headaches,
dizziness, eyestrain, sweating, and disorientation (LaViola,
2000). It has been reported that as many as 80% of
participants experience an increase in symptoms within
10 min of being exposed to VR (Kim et al., 2005; Cobb
et al., 1999), and although these studies pre-date consumer
VR, recent research indicates that this issue is still prevalent
(Yildirim, 2020).
Although it’s clear that side effects from VR exposure exist,
there is a lack of consistency in the literature regarding the precise
definitions. Rebenitsch and Owen (2016) describe the symptoms
of cybersickness produced in users of VR systems to “mimic
motion sickness, but due to the absence of actual physical motion
this affliction is considered a distinct condition referred to as
cybersickness.” Cybersickness has been referred to also as visually
induced motion sickness (VIMS), virtual simulation sickness,
virtual reality-induced symptoms and effects, amongst other
terms, as well as commonly being misinterpreted as simulator
sickness. Cybersickness is distinctly separate from simulator
sickness by the characteristics of its symptom profile, and the
apparent disparity in symptom intensity (Stanney et al., 1997).
There is some discussion in the literature regarding other
terms for these effects, for example ‘virtual reality-induced
symptoms and effect’ (Cobb et al., 1999). However, for clarity,
in this paper we will refer to the side effects of VR exposure as
‘Cybersickness,’ as this is the term most commonly used in the
literature under discussion. We acknowledge that future work in
this field should be considering updated terminology in order to
describe the symptoms.
The safety of a device or intervention should be paramount
when determining whether it is suitable for its intended audience,
especially when developing novel applications for the purpose of
medical interventions, rehabilitation, or training.
For clinical VR research, it is common to evaluate whether the
VR system causes cybersickness symptoms, and thus determining
whether it is safe to implement compared to an alternative
intervention. For example, VR is being used more commonly
within military environments where retention of information and
task performance is vital, and thus information inhibition caused
by cybersickness symptoms is an important consideration
(Stanney et al., 2020).
Aside from the safety considerations, cybersickness may have
implications for other factors in immersive systems. It has been
suggested that individuals who report greater sickness symptoms
in VR could be expected to report less presence (Witmer and
Singer, 1998; Weech et al., 2019), which may have unwanted
effects on desired outcomes. For example, when VR is used for the
purposes of pain distraction, presence is considered a major
contributor toward pain alleviation being achieved (Hoffman
et al., 2004; Wiederhold et al., 2014). It is therefore important
to test for factors, such as, cybersickness, which could potentially
affect treatment outcomes. It is recommended that applications
should be tested for cybersickness, and evaluated at the feasibility
stage (Lubetzky et al., 2018; Davis, Nesbitt, and Nalivaiko, 2015).
Cybersickness is traditionally measured using self-report
questionnaires, with the most commonly used being the
Simulator Sickness Questionnaire (SSQ) (Kennedy et al.,
1993). The SSQ was developed for use with simulators, and
was adapted from Kennedy’s work in developing the
Pensacola Motion Sickness Questionnaire (Kennedy et al.,
1965), however it has been adopted widely for use with
Virtual Environments (VE), as their symptom profiles and
sickness characteristics are similar (Stanney et al., 1997).
A number of other self-assessment questionnaires have been
devised for monitoring cybersickness, such as the Virtual Reality
Symptom Questionnaire (Ames et al., 2005), and the Virtual
Reality Sickness Questionnaire (Kim et al., 2018)–an adaption of
Kennedy’s SSQ, have been used sporadically. A common
criticism of these self-report questionnaires has been that they
take too long to administer, therefore shorter single question
measures have been used also (Nalivaiko et al., 2015; Keshavarz
and Hecht, 2011). Aside from questionnaires, assessment of
cybersickness by means of postural instability has been used
more recently (Risi and Palmisano, 2019), as postural stability has
been suggested to be a cause of the experience of cybersickness (as
it has similarly been hypothesised to be a contributing factor in
the cause of simulator sickness) (Stoffregen et al., 2000), although
conflicting opinions exist (Dennison and D’Zmura, 2017).
There is a surprisingly limited discussion in the literature
regarding what is considered a ‘normal’ score for cybersickness
amongst healthy or non-healthy populations. In relation to the
SSQ, amongst healthy participants, it is not usually necessary to
perform sickness questionnaires pre-exposure as a baseline SSQ
score could reasonably be assumed to be 0 (indicating no
symptoms). However, participants from clinical populations
may exhibit symptoms similar to cybersickness pre-exposure,
and thus for these populations, the assumed zero baseline may be
incorrect. For example, Bouchard et al. (2009) reported non-zero
pre-exposure scores amongst participants with selected anxieties.
Kennedy et al. (1993) did suggest that pre-exposure screening
of participants should be administered, but went onto
recommend that individuals in a state other than their usual
fitness (who score a non-zero pre-exposure score) should be
eliminated from further participation, and thus only post-
exposure assessment should be scored. However, if we only
test on healthy participants, we can never test with clinical
populations (such as people with chronic pain). Likewise, if we
removed the participants who answered as anything other than
‘well,’ we would be removing the target population we are trying
to study, which in turn would not facilitate clinical work being
conducted. Amongst clinical populations such as chronic pain
patients, it would certainly be counter-productive to eliminate
individuals in this capacity as it has been suggested that
confounders between cybersickness and medication exists
(McCauley and Sharkey, 1992). Furthermore, understanding
the pre-exposure state is important, as any pre-exposure
symptoms could influence the interpretation of post-exposure
scoring (Kennedy et al., 1993). Thus we suggest that it would be
more informative to assess cybersickness pre-exposure, and
observe changes which may occur between pre and post-
exposure assessment. Without pre-exposure assessment,
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incorrect conclusions about the effect of a VR intervention could
be formulated.
In lieu of pre-exposure assessment via SSQ, instruments such
as, the Motion Sickness Susceptibility Questionnaire (Golding,
1998) may be administered to assess susceptibility to symptoms.
However, susceptibility questioning alone does not reflect the
current state of patients, but rather previous experiences within
motion sickness-inducing situations, which is not indicative of
determining the effect of a VR intervention.
To date, much of the pain research concerned with pain
populations does not include any type of sickness assessment
as part of their study protocols–including post-exposure sickness
questionnaires. However, there are a few which do measure or
discuss pre-exposure baseline or pre-exposure symptoms (e.g.,
Sarig Bahat et al., 2015; Wiederhold et al., 2014; Bouchard et al.,
2009). Kennedy et al. (1993) suggested that sickness susceptibility
questionnaires could be used as an alternative to pre-exposure
baseline testing. However, in the majority of pain research in VR,
neither this nor other pre-exposure baseline symptom testing
measure is used, nor is the potential need for them discussed.
Furthermore, susceptibility questionnaires do not elicit data
regarding current symptoms, and therefore do not address the
issue of a non-zero baseline score.
As the SSQ is currently the most widely use measure for
cybersickness, we use this measure pre and post-exposure in
order to facilitate comparisons with other work. The most
common approach for assessing results of the SSQ is Kennedy
et al.’s. weighted scoring (1993), although this has been
criticised for scores being inflated by counting items
multiple times in the total score calculation (Bouchard
et al., 2007). Alternative scoring methodologies have been
proposed, such as Bouchard et al. (2007) revised factor
structure which proposes assessment with raw scores, rather
than Kennedy’s weighted score calculation.
We suggest that it is important to understand whether some
clinical populations may present pre-existing symptoms similar
to symptoms of cybersickness (H1). Furthermore, it has been
observed previously that cybersickness symptom scores may
decrease rather than increase as the result of a VR
intervention, (e.g., Bouchard et al. , 2009). A decrease in
cybersickness-like symptoms in such a population may still
give a post-exposure score greater than the zero baseline (H2).
It could be hypothesised that a direct comparison of post-
exposure SSQ scores between healthy and pain populations
cybersickness scorings post-VR intervention may indicate that
an intervention has made the pain population sicker than the
healthy population. However, if pre-exposure (baseline)
cybersickness scores were taken into account, then it may be
that the any difference is due to a baseline difference, and not
caused by the intervention itself (H3).
H1—The pain population will have significantly higher pre-
exposure SSQ scores than the normal population assumed
baseline.
H2—The pain population will have significantly higher post-
exposure SSQ scores than the normal population assumed
baseline of zero.
H3—The difference in SSQ scores from pre-exposure to post-
exposure will be significantly less than the difference between
the assumed baseline score and the post-exposure score.
METHODS
The participants for this study were drawn from a population of
Chronic Pain patients, as this group has been identified as one
which may present pre-existing symptoms (McCauley and
Sharkey, 1992). In order to reduce the burden on the patient
population, this SSQ study was conducted alongside a study
observing the effect of VR on experimentally induced pain in
Chronic Pain patients, which describes the study methods and
procedure summarised here in more depth.
Participants
Twelve participants aged 39–70 (M  56 ± 9.36) (Table 1) were
recruited from a United Kingdom pain support group and
networks. All participants had been experiencing chronic pain
(defined as a period lasting 3 months or greater). Participants also
completed pre-study screening questionnaires to exclude any
factors which would prevent them from participating in a VR
study. Factors for exclusion included health issues which could
prevent someone from using a visual display for an extended
period of time.
Design
A within-subjects, repeated measures study design was used.
Pre-exposure SSQ was recorded before participants were
randomised to receive either an active or passive VR
distraction in a counterbalanced order. The passive
intervention was part of the parallel study and is not
considered further in this paper. In line with previous
literature relating to SSQ scores, in this study we are only
considering post-active SSQ results referred to hereon as post-
exposure, unless explicitly stated otherwise.
Hardware and Software
The software interventions used were 1) Bananaland. An active
intervention and a proprietary VR experience, in which the user
traverses through a jungle environment with ambient music
accompanying the visuals. 2) A passive intervention which
consisted of grey lines on the screen. In this condition users
could look around however no dynamic visual feedback was
present. This was designed to be neutral and non-engaging.
Both interventions were presented using an Oculus Rift CV1
Head Mounted Display (HMD).
TABLE 1 | Participant demographical information.
Male Female
Gender (N) 5 7
Nociceptive Neuropathic Unknown
Cause of pain (N) 8 3 1
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Procedure
Participants were asked to sign a consent, and were asked to
confirm that no changes had occurred since registering that might
be applicable to the studies medical exclusion criteria.
Before any VR intervention, participants completed a pre-
exposure (baseline) SSQ. As per the protocol for the
accompanying study, participants were induced with
experimental pain by means of a pressure cuff inflated to and
sustained at 200 mmHg, and applied to their non-dominant arm.
This procedure was conducted in accordance with the
Submaximal Tourniquet Effort Test (SMET) (Moore et al., 1979).
Participants were then exposed to the VR intervention for a
maximum of 5 min, or until the participant asked to exit, which
they were able to do at any point. After the completion of each VR
session, participants completed a post-exposure SSQ. After each
session, the participant was given time to rest before continuing.
The study was approved by the University of Portsmouth
institutional review board.
Data Analysis
A Shapiro–Wilk test of normality indicated that pre-test sickness
scoring was not normally distributed (p  0.001). A Shapiro-wilk
test of normality indicated that the post-test sickness scoring was
not normally distributed (p  0.014).
As this work is concerned with being comparable in the relevant
literature, we will be calculating our results using Kennedy’s
traditional approach, although will also apply Bouchard et al.
(2007) revised factor structure and scoring where applicable.
A Wilcoxon signed-rank test was performed to assess whether
our study sample had a significantly higher pre-exposure SSQ
scores than the normal population assumed baseline. AWilcoxon
signed-rank test was performed to assess whether our study
sample had a significantly higher post-exposure SSQ scores
than the normal population assumed baseline. A Mann-
Whitney U test was performed to assess whether the
difference in SSQ scores from pre and post-exposure of our
study sample will be significantly less than the difference the
assumed baseline score and the post-exposure score of our study
sample.
RESULTS
Descriptive statistics for the pre-exposure and both post-exposure
SSQ scores are shown in Table 2, and Figures 1 and 2.
All scores referred to as weighted have been calculated using
Kennedy et al. 1993) method. References to non-weighted scores
are applying Bouchard et al. (2007) scoring approach.
(1) Pre-exposure SSQ scores compared to the assumed baseline
(zero) of healthy participants.
A Wilcoxon signed-rank test indicated that the pre-exposure
scores were significantly greater than the assumed baseline (zero)
(z  55, p  0.005).
(2) Post-exposure SSQ scores compared to the assumed baseline
(zero) of healthy participants.
A Wilcoxon signed-rank test indicated that a significantly
higher post-exposure score than the assumed baseline (zero) was
reported (z  66, p  0.003).
The mean post-exposure score obtained from our participants
was 18.39, with high variability as the SD for the post-exposure
was 16.19 (Table 1).
(3) Comparing post-exposure differences between actual and
assumed baseline SSQ scores
AMann–WhitneyU test indicated that the difference between
the pre and post-exposure SSQ scores was significantly less than
the difference between the assumed baseline and post-exposure
SSQ score (z  −2.297, p  0.020) (Figure 3).
A Mann-Whitney U test performed using Bouchard et al.
(2007) non-weighting scoring approach indicated that the
difference between the pre and post-exposure SSQ scores was
significantly less than the difference between the assumed
baseline and post-exposure SSQ score (z  −2.297, p  0.020).
Individual items of the SSQ are categorised into subscales
which are distinct symptom clusters (Kennedy et al., 1993). We
TABLE 2 | Pre and post exposure SSQ scores for pain participants.
Participant Pre-exposure baseline
(weighted)






1 7.48 2 18.7 5
2 7.48 2 14.96 4
3 0 0 0 0
4 44.88 12 33.66 9
5 0 0 3.74 1
6 11.22 3 11.22 3
7 7.48 2 63.58 17
8 3.74 1 3.74 1
9 14.96 4 22.44 6
10 7.48 2 14.96 4
11 3.74 1 14.96 4
12 14.96 4 18.7 5
Mean 10.29 2.75 18.39 4.92
SD 11.44 3.19 16.19 4.52
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therefore also scored each symptom cluster independently
(Table 3).
There was an approximately 10 point increase in mean weighted
SSQ scores in each of the sub categories, with the greatest variability
being observed in the disorientation sub category.Whilst increases in
mean SSQ scores were noted in all three categories, the symptom
profile remained the same pre and post exposure.
DISCUSSION
In this study, we theorised that using post-exposure SSQ
scores in VR studies may lead to misinterpretation of results
in some clinical populations such as those with chronic pain.
To investigate this, we formulated three hypotheses
regarding how pain participants cybersickness scores
would compare to an assumed baseline scoring of the
healthy population, and whether the pre-exposure state of
pain participants differs from healthy participants assumed
baseline.
We first hypothesised that a chronic pain population will
have a higher than zero baseline SSQ score than the normal
population. Our results indicate that a significant difference
between the assumed (zero) baseline, and the measured pre-
exposure SSQ scores exists, supporting the hypothesis. Much
of the existing literature relies on post-exposure SSQ scores
FIGURE 1 | Weighted total severity SSQ scores pre-exposure and post-exposure of VR interventions.
FIGURE 2 | Non-weighted total severity SSQ scores pre-exposure and post-exposure.
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only, and few studies to date are concerned with determining
the pre-exposure condition (Sarig Bahat et al., 2015;
Wiederhold et al., 2014). Whilst this may be of limited
importance if we are only interested in absolute SSQ score
post-exposure, it becomes highly relevant when comparing
the effect of VR exposure between different populations. We
cannot assume that all population sub-groups will be starting
studies at the same baseline, and this could affect the
interpretation of post-exposure scores.
Secondly, we hypothesised that a chronic pain population
will have greater post-exposure SSQ scores than the assumed
(zero) baseline. Our results indicate that a significant
difference does indeed exist. We expect with a VR
intervention that participants will report some, potentially
significant, cybersickness post-exposure, as it is unlikely to
be zero. However, when assuming the comparison against a
zero baseline, the result is not necessarily indicative of the
VR interventions causation. This highlights potential
disparities when using assumed baselines amongst groups
such as chronic pain participants (who likely enter studies
with elevated baselines). Furthermore, one participants
cybersickness symptoms actually decreased between pre
and post-VR intervention (Figure 1), supporting similar
observations made by Bouchard et al. (2009). This result
also supports our first hypothesis that assuming baselines
can affect the interpretation of post-exposure scoring.
Thirdly, we hypothesised that the difference between SSQ
scores of the pre and post-exposure would be significantly
less than the difference between the assumed baseline and
the post-exposure SSQ scores. Our results demonstrated that
the difference in SSQ scores measured pre to post was
significantly less than the difference in SSQ scores
measured between the assumed baseline and post-
exposure (Figure 3). If we aim to determine whether an
intervention has caused cybersickness, by just collecting and
observing post-exposure scores we may conclude that it does
(when compared to zero). However, if we are able to look at
our populations incoming SSQ score, it may be that the
intervention has little or no negative effect by comparison.
Furthermore, this result demonstrates how if these results
were analysed without a known baseline and just the
assumed (zero) baseline, that a false positive effect of the
intervention on SSQ would have been reported. In the
absence of pre-exposure or susceptibility testing (Golding,
1998), just post-exposure SSQ scoring could indicate that the
pain population would become sicker than the healthy
population, and could ultimately conclude that an
application is unsuitable for the non-healthy population.
FIGURE 3 | Post exposure differences between actual and assumed baseline SSQ scores.
TABLE 3 | SSQ symptom sub category scores.
Mean SD Min Max
Oculomotor
Pre-exposure (weighted) 18.318 19.439 0 75.8
Pre-exposure (non-weighted) 1.417 2.431 0 9
Post-exposure (weighted) 25.267 18.908 0 68.22
Post-exposure (non-weighted) 2.167 2.375 0 8
Nausea
Pre-exposure (weighted) 15.105 13.184 0 47.7
Pre-exposure (non-weighted) 1.33 1.027 0 3
Post-exposure (weighted) 23.055 11.327 0 38.16
Post-exposure (non-weighted) 2.75 2.203 0 9
Disorientation
Pre-exposure 2.32 7.695 0 27.84
Post-exposure 12.76 34.781 0 125.28
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However, if pre-exposure testing is conducted, it’s possible
that the rate of change in both populations is comparable,
and therefore the application is equally suitable for both.
This is of particular importance for pain populations, as
the literature highlights how cybersickness may be negatively
correlated with presence (Witmer and Singer, 1998; Weech
et al.,, 2019), which is considered a key reason for VR’s
efficacy of providing pain alleviation via distraction, as it’s
suggested to be positively correlated with presence (Hoffman
et al., 2004; Wiederhold et al., 2014).
While difference scoring alone is not generally considered a
valid measure due to potentially poor reliability (Cronbach and
Furby, 1970; Young et al., 2006), our result nevertheless
demonstrates the importance of understanding pre-exposure
symptoms of a clinical population when examining the effect
of cybersickness When considering whether the symptoms of
cybersickness become exacerbated in a VR application, basing our
assumptions on purely on the post-exposure SSQ scores would be
misleading.
The SSQ categorises symptoms into three distinct clusters
which are Oculomotor, Nausea, and Disorientation (Kennedy
et al., 1993). Spectral profiles of sickness exist to define
cybersickness from the often misinterpreted simulator
sickness (Stanney et al., 1997), with simulator sickness
following the symptom profile of Oculomotor, Nausea, and
Disorientation; in order of perceived symptom severity.
Cybersickness however is suggested to follows the
symptom profile of Disorientation, Nausea, and
Oculomotor (Stanney et al., 1997) (Table 4). Although
examining the differences between the SSQ subcategories
was not a primary aim of this study, and is thus purely
observational, we noted that the reported SSQ symptoms
did not follow the symptom profiles which traditionally
defines cybersickness uniquely (Figure 4). We observed
that the symptom profile of participants was similar to
that of simulator sickness (Table 4), rather than that of
cybersickness. The literature has previously highlighted
discrepancies in cybersickness/simulator sickness spectral
profile definitions, suggesting that users affected with
cybersickness have followed symptom profiles different to
that reported by Stanney et al. (1997) and Gavgani et al.
(2018). Although this cannot be generalised for the
population as this is a small sample, this effect should be
looked into further with a larger sample.
This could be because rather than following symptom
profiles devised to categorise cybersickness, pain
participants are exhibiting symptoms associated with
chronic pain symptom profiles. For example, at pre and
post-exposure our participants scored highest in
Oculomotor and Nausea (Table 3). Oculomotor elements
include fatigue, headache, eye strain, and difficulty focusing,
similar to some somatic symptoms associated with chronic
pain which includes fatigue, unrefreshing sleep, and
dyscognition (difficulty concentrating and thinking) (Wolfe
et al., 2010; Crofford, 2015). Nausea elements include feeling
nauseous and dizziness, which are also common side effects of
opioid based medication, such as Hydrocodone and Fentanyl,
commonly prescribed for the treatment of chronic pain
(Benyamin et al., 2008). However, when observing the rate
of increase between pre and post-exposure, the rate of which
symptoms have increased is comparable to the traditionally
proposed symptom severity of cybersickness (Figure 4). This
would indicate that participants entered with symptoms of
their illness, which is comparable to Simulator Sickness and
pain symptom profiles, however their increase is
representative of cybersickness. Future work could further
investigate the symptom profiles of clinical sub-populations
TABLE 4 | Severity of symptoms in spectral profiles.




FIGURE 4 | SSQ total severity and symptom category scores.
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pre and post-exposure, which may give some indication as to
whether post-exposure SSQ scores are more attributable to the
VR intervention or the pre-existing clinical condition.
It’s also possible that the experimentally induced painful
stimuli experienced during the parallel study may have caused
an increase in the pain-related symptoms, which overlap with
the SSQ symptom list. Further studies using a VR exposure for
this group without the experimentally induced pain would
control for this possible confounding factor. It has be argued
that pre-exposure may influence post-exposure results (Kim
et al., 2005; Young et al., 2006). In these previous studies they
show a significant increase when given pre-exposure
questionnaires, an effect which we did not observe. Future
work could explore pre-exposure bias when administering the
SSQ further.
Two participants reported a pre-exposure SSQ score
comparable to the normal populations assumed baseline
(zero), with the mean pre-exposure SSQ for the pain
participants being 10.29. A high SD of 11.44 was reported,
indicating that reported pre-exposure SSQ scores were highly
variable (Table 1), which is representative of pain populations
variability and individuality of symptom exhibition (Allen
et al., 2009; Bartley et al., 2018). Of the 12 participants, 9
had a post-exposure score greater than 10, only 2 of these
showed a substantial increase on pre-exposure scores, and all 9
had a non-zero pre-exposure score. However, 1 participant did
show a decrease is symptoms as oppose to an increase
(Figure 1).
Using Bouchard et al. (2007) scoring approach, a
comparable Mann-Witney U test was performed which
returned the same confidence interval as we observed
when using Kennedy’s scoring. Similar differences were
also observed when scoring the Nausea and Oculomotor
sub-scales respectively (Figure 5). Therefore, although in
other contexts Bouchard’s scoring may give rise to
different conclusions, for the purposes of this study both
Bouchard’s and Kennedy’s approaches lead to the same
conclusions.
We would like to acknowledge also that although the
focus of this work was to highlight that certain
populations may not be as adversely affected as SSQ
scores might indicate, it is possible that starting with a
non-zero pre-score might mean that when participants do
become sick because of VR, the rate which their sickness
increases may be greater than someone who entered the
study with a zero baseline score. Alternatively, entering
with a non-zero baseline score could also provide greater
resilience to symptoms when interacting within VR.
Kruk,(1992) suggests that medication increases the
susceptibility to simulator sickness. Although little work
exists as to whether this same interaction exists for
cybersickness, McCauley and Sharkey 1992) suggest that
problems with cybersickness symptoms may be
exacerbated by medication. Further work could be
warranted to explore these points.
This study has highlighted that some sub-populations
cannot be assumed to have a zero baseline. 10 out of 12
participants enrolled in this study entered with a non-zero
baseline, confirming that assumed baselines should not be an
indicator for informed research concerned with measuring
cybersickness amongst non-healthy populations. and that
considerations should be taken when evaluating the
usability of VR systems or interventions for participants
from different demographics.
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